People around the world will need to get a jab against Covid-19 once a year, at least when it comes to the Pfizer vaccine, BioNTech’s CEO Ugur Sahin said in an interview on Sunday, as he praised the quality of its booster shot.
In an interview with Germany’s Bild newspaper on Sunday, Sahin said he considers the vaccine, co-developed by his company, to be “very effective.”
When asked whether people should be worried about the “breakthrough infections” – in which those vaccinated with the Pfizer-BioNTech vaccine still developed Covid-19 symptoms – he dismissed such concerns, saying that the jab offers a “90 percent protection” against cases that require intensive care in those aged over 60.
A “very high” level of protection against severe illness lasts for up to nine months, the BioNTech CEO maintained. He said this level starts decreasing “from the fourth month,” however. To maintain the protection, Sahin strongly pushed for booster shots, arguing that they would not just restore levels of antibodies but would potentially help “to break … chains of infection.”
He also encouraged doctors to be “as pragmatic as possible” when it comes to greenlighting vaccination and “not to send people home unvaccinated even though they could be vaccinated without any problems.”
In the future, people might need to get booster shots once a year, the BioNTech CEO believes. He said that he expects protection from a booster shot to “last longer” than the initial immunity one acquires after getting two doses of the vaccine.
“Subsequent … vaccinations may only be needed every year – just like [with] influenza,” he said. Currently, the German Federal Center for Health Education – an agency subordinated to the Health Ministry – recommends a booster shot six months after one gets the second dose of a vaccine. It also says that “booster vaccination makes sense after a minimum interval of about four months.”
Sahin’s interview comes days after it was revealed that Pfizer, BioNTech and Moderna are making a combined profit of $65,000 every minute – all thanks to their Covid-19 jabs. That is according to estimates made by the People’s Vaccine Alliance (PVA) – a coalition demanding wider access to vaccines.
The PVA estimated that the three companies are to earn a total of $34 billion in combined pre-tax profits this year alone, which roughly translates into more than $1,000 a second and $93.5 million a day.
PVA has slammed the three companies over their refusal to allow vaccine technology transfer despite receiving a combined $8 billion in public funding. Such a move could increase global supply and save millions of lives as well as drive down prices, the coalition said.
“Pfizer, BioNTech and Moderna have used their monopolies to prioritize the most profitable contracts with the richest governments, leaving low-income countries out in the cold,” said Maaza Seyoum of the African Alliance and People’s Vaccine Alliance Africa.
Think your friends would be interested? Share this story!
The EU’s drug regulator has backed the emergency use of Merck’s pill for the treatment for clinically vulnerable Covid-19 patients as cases surge across the continent.
On Friday, the European Medicines Agency (EMA) “issued advice” backing the emergency use of the drug developed by Merck in collaboration with Ridgeback Biotherapeutics, although it has not yet been authorized by national authorities.
In a statement, the drug regulator said the medicine called Lagevrio – also known as molnupiravir or MK 4482 – “can be used to treat adults with Covid-19 who do not require supplemental oxygen and who are at increased risk of developing severe Covid-19.”
It said the treatment should be administered as soon as possible after Covid-19 is diagnosed and within five days of the start of symptoms. The medicine should be taken twice a day for a period of five days.
The EMA listed the potential side effects of the capsules, including mild or moderate diarrhea, nausea, dizziness and headache. The treatment is not recommended for pregnant women.
The watchdog announced earlier on Friday that it had begun reviewing Pfizer’s medicine Paxlovid for Covid-19 with the same goal “to support national authorities” who may decide on its early use prior to marketing authorization in light of rising cases and deaths in Europe.
On Friday, Austria announced it would enter a new nationwide lockdown from Monday and make vaccination mandatory, while Germany’s health authorities claimed the country had turned into “one big outbreak.”
Both Pfizer and Merck have requested approval for their coronavirus medicines from the US Food and Drug Administration, but it is unclear when it might be granted.
Think your friends would be interested? Share this story!
